HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) pathology has been associated with Tax protein secreted from HTLV-1 infected CD4+-T-lymphocytes, which interacts with soluble SEMA-4D (Semaphorin 4D) inducing growth cone collapse in neurons. We investigated HTLV-1-induced phenotypic and signaling changes during PC12 neuronal differentiation that may mediate growth cone collapse effects. We measured kinases and phosphatases associated with microtubule-associated proteins and molecular motor functions. Phosphorylation status of proteins that participate in the cytoskeleton and axonal transport such as Tau, microtubule-associated protein 1B (MAP1B), motor proteins (kinesin-1 and dynein) and collapsin response mediator protein (CRMP-2), all involved in neurite extension and branching, were measured. The phosphorylation/dephosphorylation of these proteins is catalyzed by Cyclin-dependent kinase-5 (CDK5), Glycogen synthase kinase-3β (GSK3β), and Protein phosphatase-2 (PP2A). Our results show that viral secreted proteins produced a reduction of neurite extension and branching in PC12 cells during neuronal differentiation. We observed that GSK3β activity increased, while CDK5 and PP2A activities decreased. In addition, we found reduced levels of Tau phosphorylated at Thr181 and increased levels of CRMP-2 phosphorylated at Ser522. No changes in motor proteins or MAP1B phosphorylation were found. Neurotoxic effects of HTLV-1 secreted proteins on neuronal differentiation of PC12 cells include lower CDK5 activity, which could explain the reduced levels of Tau-(pThr181); this could induce conformational changes in Tau protein, altering microtubule dynamics. Increased CRMP-2-(pSer522) phosphorylation precedes further phosphorylation at Thr509/514 residues by GSK3β. All these phosphorylations are associated with growth cone collapse. The increased CRMP-2-(pSer522) levels found here suggest that CDK5 activity, even when decreased, is sufficient for this priming phosphorylation. Reduction in PP2A activity could importantly contribute to maintaining the increased phosphorylation in CRMP-2. These results suggest the involvement of extracellular Tax/sSEMA-4D complex in the activation of Plexin1B receptor, activating downstream cascade involving PI3K/AKT/GSK3β/CRMP-2, inducing growth cone collapse.
YamanoY, SatoT. Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis. Front Microbiol, 2012; 3:389; doi: 10.3389/fmicb.2012.00389
3.
MiuraM, TadasukeT, SaitoM. Current perspectives in human T-Cell leukemia virus type 1 infection and its associated diseases. Front Med (Lausanne), 2022; 9:867478; doi: 10.3389/fmed.2022.867478
4.
CartierL, VergaraA, ValenzuelaMA. Immunohistochemistry of degenerative changes in the central nervous system in spastic paraparesis associated to human T lymphotropic virus type I (HTLV-I). Rev Med Chile, 2007; 135:1139–1146; doi: 10.4067/s0034-98872007000900007
Bastos FerreiraAP, do NascimentoADFS, Sampaio Rocha-FilhoPA. Cerebral and spinal cord changes observed through magnetic resonance imaging in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis: A systematic review. J Neurovirol, 2022; 28(1):1–16; doi: 10.1007/s13365-021-01043-2
7.
ForlaniG, ShallakM, AccollaRS, et al.HTLV-1 infection and pathogenesis: New insights from cellular and animal models. Int J Mol Sci, 2021; 22(15):8001; doi: 10.3390/ijms22158001
8.
CartierL, RamirezE. Presence of HTLV-I Tax protein in cerebrospinal fluid from HAM/TSP patients. Arch Virol, 2005; 150(4):743–753; doi: 10.1007/s00705-004-0443-3
9.
MedinaF, QuintremilS, AlbertiC, et al.Tax secretion from peripheral blood mononuclear cells and Tax detection in plasma of patients with human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis and asymptomatic carriers. J Med Virol, 2016; 88(3):521–531; doi: 10.1002/jmv.24342
10.
QuintremilS, AlbertiC, RiveraM, et al.Tax and Semaphorin 4D released from lymphocytes infected with human lymphotropic virus Type 1 and their effect on neurite growth. AIDS Res Hum Retroviruses, 2016; 32(1):68–79; doi: 10.1089/aid.2015.0008
11.
YamauchiJ, ArayaN, YagishitaN, et al.An update on human T-cell leukemia virus type I (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) focusing on clinical and laboratory biomarkers. Pharmacol Ther, 2021; 218:107669; doi: 10.1016/j.pharmthera.2020.107669
12.
MartinsML, de Freitas Carneiro-ProiettiAB, NicolatoR, et al.HTLV-1 proviral load in cerebrospinal fluid may not be a good marker to differentiate asymptomatic carriers with high proviral load in blood from HAM/TSP patients. J Neurovirol, 2018; 24(4):432–438; doi: 10.1007/s13365-018-0632-6
13.
NakamuraT. HAM/TSP pathogenesis: The transmigration activity of HTLV-1-infected T cells into tissues. Pathogens, 2023; 12(3):492; doi: 10.3390/pathogens12030492
14.
MedinaF, QuintremilS, AlbertiC, et al.Tax posttranslational modifications and interaction with calreticulin in MT-2 cells and human peripheral blood mononuclear cells of human T cell lymphotropic virus type-I-associated myelopathy/tropical spastic paraparesis patients. AIDS Res Hum Retroviruses, 2014; 30(4):370–379; doi: 10.1089/AID.2013.0036
15.
Varrin-DoyerM, NicolleA, MarignierR, et al.Human T lymphotropic virus type 1 increases T lymphocyte migration by recruiting the cytoskeleton organizer CRMP2. J Immunol, 2012; 188(3):1222–1233; doi: 10.4049/jimmunol.1101562
16.
GiraudonP, NicolleA, CavagnaS, et al.Insight into the role of CRMP2 (Collapsin Response Mediator Protein 2) in T lymphocyte migration: The particular context of virus infection. Cell Adh Migr, 2013; 7(1):38–43; doi: 10.4161/cam.22385
17.
PasterkampRJ, GigerJ. Semaphorin function in neural plasticity and disease. Curr Opin Neurobiol, 2009; 19(3):263–274; doi: 10.1016/j.conb.2009.06.001
18.
ZhouY, GunputRA, PasterkampRJ. Semaphorin signaling: Progress made and promises ahead. Trends Biochem Sci, 2008; 33(4):161–170; doi: 10.1016/j.tibs.2008.01.006
19.
NakamuraF, OhshimaT, GoshimaY. Collapsin response mediator proteins: Their biological functions and pathophysiology in neuronal development and regeneration. Front Cell Neurosci, 2020; 14:188; doi: 10.3389/fncel.2020.00188
20.
UmeharaF, AbeM, KoreedaY, et al.Axonal damage revealed by accumulation of beta-amyloid precursor protein in HTLV-I-associated myelopathy. J Neurol Sci, 2000; 176(2):95–101; doi: 10.1016/s0022-510x(00)00324-5
21.
StokinGB, GoldsteinLS. Axonal transport and Alzheimer’s disease. Annu Rev Biochem, 2006; 75:607–627; doi: 10.1146/annurev.biochem.75.103004.142637
22.
BerthSH, LloydTE. Disruption of axonal transport in neurodegeneration. J Clin Invest, 2023; 133(11):e168554; doi: 10.1172/JCI168554
23.
GuoW, Stoklund DittlauK, Van Den BoschL. Axonal transport defects and neurodegeneration: Molecular mechanisms and therapeutic implications. Semin Cell Dev Biol, 2020; 99:133–150; doi: 10.1016/j.semcdb.2019.07.010
24.
GibbsKL, GreensmithL, SchiavoG. Regulation of axonal transport by protein kinases. Trends Biochem Sci, 2015; 40(10):597–610; doi: 10.1016/j.tibs.2015.08.003
25.
KimuraT, IshiguroK, HisanagaS. Physiological and pathological phosphorylation of tau by Cdk5. Front Mol Neurosci, 2014; 7:65; doi: 10.3389/fnmol.2014.00065
26.
VenkatramaniA, PandaD. Regulation of neuronal microtubule dynamics by tau: Implications for tauopathies. Int J Biol Macromol, 2019; 133:473–483; doi: 10.1016/j.ijbiomac.2019.04.120
27.
BarbierP, ZejneliO, MartinhoM, et al.Role of Tau as a microtubule-associated protein: Structural and functional aspects. Front Aging Neurosci, 2019; 11:204; doi: 10.3389/fnagi.2019.00204
28.
YangM, WuM, XiaP, et al.The role of microtubule-associated protein 1B in axonal growth and neuronal migration in the central nervous system. Neural Regen Res, 2012; 7(11):842–848; doi: 10.3969/j.issn.1673-5374.2012.11.008
CrewsL, RufR, PatrickC, et al.Phosphorylation of collapsing response mediator protein-2 disrupts neuronal maturation in a model of adult neurogenesis: Implications for neurodegenerative disorders. Mol Neurodegener, 2011; 6:67; doi: 10.1186/1750-1326-6-67
31.
KumariD, RayK. Phosphoregulation of kinesins involved in long-range intracellular transport. Front Cell Dev Biol, 2022; 10:873164; doi: 10.3389/fcell.2022.873164
32.
GaoFJ, HebbarS, GaoXA, et al.GSK‐3β phosphorylation of cytoplasmic dynein reduces Ndel1 binding to intermediate chains and alters dynein motility. Traffic, 2015; 16(9):941–961; doi: 10.1111/tra.12304
33.
BradyST, MorfiniGA. Regulation of motor proteins, axonal transport deficits and adult-onset neurodegenerative diseases. Neurobiol Dis, 2017; 105:273–282; doi: 10.1016/j.nbd.2017.04.010
34.
ChengP, ChenK, YuW, et al.Protein phosphatase 2A (PP2A) activation promotes axonal growth and recovery in the CNS. J Neurol Sci, 2015; 359(1–2):48–56; doi: 10.1016/j.jns.2015.10.025
35.
HoffmanA, TaleskiG, SontagE. The protein serine/threonine phosphatases PP2A, PP1 and calcineurin: A triple threat in the regulation of the neuronal cytoskeleton. Mol Cell Neurosci, 2017; 84:119–131; doi: 10.1016/j.mcn.2017.01.005
36.
HangerDP, AndertonBH, NobleW. Tau phosphorylation: The therapeutic challenge for neurodegenerative disease. Trends Mol Med, 2009; 15(3):112–119; doi: 10.1016/j.molmed.2009.01.003
37.
XingH, LimYA, ChongJR, et al.Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with β-amyloid burden and synaptic deficits in Lewy body dementias. Mol Brain, 2016; 9(1):84; doi: 10.1186/s13041-016-0264-9
38.
ZhuLQ, ZhengH-Y, PengC-X, et al.Protein phosphatase 2A facilitates axonogenesis by dephosphorylating CRMP2. J Neurosci, 2010; 30(10):3839–3848; doi: 10.1523/JNEUROSCI.5174-09
39.
WangC, CuiY, XuT, et al.New insights into glycogen synthase kinase-3: A common target for neurodegenerative diseases. Biochem Pharmacol, 2023; 218:115923; doi: 10.1016/j.bcp.2023.115923
40.
WangY, MandelkowE. Tau in physiology and pathology. Nat Rev Neurosci, 2016; 17(1):5–21; doi: 10.1038/nrn.2015.1
41.
HensleyK, KursulaP. Collapsin response mediator protein-2 (CRMP2) is a plausible etiological factor and potential therapeutic target in Alzheimer’s Disease: Comparison and contrast with microtubule-associated protein Tau. J Alzheimers Dis, 2016; 53(1):1–14; doi: 10.3233/JAD-160076
42.
GaoFJ, WangN, SunFR, et al.Tau in neurodegenerative disease. Ann Transl Med, 2018; 6(10):175; doi: 10.21037/atm.2018.04.23
43.
SumiT, ImasakiT, AokiM, et al.Structural insights into the altering function of CRMP2 by phosphorylation. Cell Struct Funct, 2018; 43(1):15–23; doi: 10.1247/csf.17025
44.
MoutalA, WhiteKA, ChefdevilleA, et al.Dysregulation of CRMP2 post-translational modifications drive its pathological functions. Mol Neurobiol, 2019; 56(10):6736–6755; doi: 10.1007/s12035-019-1568-4
45.
PaoPC, TsaiLH. Three decades of Cdk5. J Biomed Sci, 2021; 28(1):79; doi: 10.1186/s12929-021-00774-y
46.
AoC, LiC, ChenJ, et al.The role of Cdk5 in neurological disorders. Front Cell Neurosci, 2022; 16:951202; doi: 10.3389/fncel.2022.951202
47.
MaldonadoH, RamírezE, UtrerasE, et al.Inhibition of cyclin-dependent kinase 5 but not of glycogen synthase kinase 3-β prevents neurite retraction and tau hyperphosphorylation caused by secretable products of human T-cell leukemia virus type I-infected lymphocytes. J Neurosci Res, 2011; 89(9):1489–1498; doi: 10.1002/jnr.22678
48.
WangJZ, Grundke-IqbalI, IqbalK. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci, 2007; 25(1):59–68; doi: 10.1111/j.1460-9568.2006.05226.x
49.
HanX, KepingC. Phosphorylation of the Tau protein in neurodegenerative disease. Biomed J Sci & Tech Res, 2020; 26; doi: 10.26717/BJSTR.2020.26.004393
50.
XiaY, ProkopS, GiassonBI. “Don’t Phos Over Tau”: Recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies. Mol Neurodegener, 2021; 16(1):37; doi: 10.1186/s13024-021-00460-5
51.
YangJ, ZhiW, WangL. Role of Tau protein in neurodegenerative diseases and development of its targeted drugs: A Literature Review. Molecules, 2024; 29(12):2812; doi: 10.3390/molecules29122812
52.
LaemmliUK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 1970; 227(5259):680–685; doi: 10.1038/227680a0
53.
Villarroel-CamposD, Gonzalez-BillaultC. The MAP1B case: An old MAP that is new again. Dev Neurobiol, 2014; 74(10):953–971; doi: 10.1002/dneu.22178
MorfiniG, SzebenyiG, BrownH, et al.A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons. Embo J, 2004; 23(11):2235–2245; doi: 10.1038/sj.emboj.7600237
56.
BarnatM, BenassyMN, VincensiniL, et al.The GSK3-MAP1B pathway controls neurite branching and microtubule dynamics. Mol Cell Neurosci, 2016; 72:9–21; doi: 10.1016/j.mcn.2016.01.001
57.
RiedererBM. Microtubule-associated protein 1B, a growth-associated and phosphorylated scaffold protein.:541–558; doi: 10.1016/j.brainresbull.2006.11.012
58.
ArimuraN, MénagerC, KawanoY, et al.Phosphorylation by Rho Kinase regulates CRMP-2 activity in growth cones. Mol Cell Biol, 2005; 25(22):9973–9984; doi: 10.1128/mcb.25.22.9973-9984.2005
59.
UchidaY, OhshimaT, SasakiY, et al.Semaphorin3A signalling is mediated via sequential Cdk5 and GSK3beta phosphorylation of CRMP2: Implication of common phosphorylating mechanism underlying axon guidance and Alzheimer’s disease. Genes Cells, 2005; 10(2):165–179; doi: 10.1111/j.1365-2443.2005.00827.x
60.
QuachTT, MoutalA, KhannaR, et al.Collapsin response mediator proteins: Novel targets for Alzheimer’s Disease. J Alzheimers Dis, 2020; 77(3)):949–960; doi: 10.3233/JAD-200721
61.
HouST. The regulatory and enzymatic functions of CRMPs in neuritogenesis, synaptic plasticity, and gene transcription. Neurochem Int, 2020; 139:104795; doi: 10.1016/j.neuint.2020.104795
62.
SainathR, GalloG. Cytoskeletal and signaling mechanisms of neurite formation. Cell Tissue Res, 2015; 359(1):267–278; doi: 10.1007/s00441-014-1955-0
63.
KevenaarJT, HoogenraadCC. The axonal cytoskeleton: From organization to function. Front Mol Neurosci, 2015; 8:44; doi: 10.3389/fnmol.2015.00044
64.
PachecoA, GalloG. Actin filament-microtubule interactions in axon initiation and branching. Brain Res Bull, 2016; 126(Pt 3):300–310; doi: 10.1016/j.brainresbull.2016.07.013
65.
PimmML, Henty-RidillaJL. New twists in actin-microtubule interactions. Mol Biol Cell, 2021; 32(3):211–217; doi: 10.1091/mbc.E19-09-0491
66.
BiswasS, KalilK. The Microtubule-associated protein Tau mediates the organization of microtubules and their dynamic exploration of Actin-rich lamellipodia and filopodia of cortical growth cones. J Neurosci, 2018; 38(2):291–307; doi: 10.1523/JNEUROSCI.2281-17.2017
67.
MadayS, TwelvetreesAE, MoughamianAJ, et al.Axonal transport: Cargo-specific mechanisms of motility and regulation. Neuron, 2014; 84(2):292–309; doi: 10.1016/j.neuron.2014.10.019
68.
HiggsVE, DasRM. Establishing neuronal polarity: Microtubule regulation during neurite initiation. Oxf Open Neurosci, 2022; 1:kvac007; doi: 10.1093/oons/kvac007
69.
HallA, LalliG. Rho and Ras GTPases in axon growth, guidance, and branching. Cold Spring Harb Perspect Biol, 2010; 2(2):a001818; doi: 10.1101/cshperspect.a001818
70.
AokiK, NakamuraT, MatsudaM. Spatio-temporal regulation of Rac1 and Cdc42 activity during nerve growth factor-induced neurite outgrowth in PC12 cells. J Biol Chem, 2004; 279(1):713–719; doi: 10.1074/jbc.M306382200
71.
KimY, SegerR, CvSB, et al.A positive role of the PI3-K/Akt signaling pathway in PC12 cell differentiation. Mol Cells, 2004; 18(3):353–359; doi: 10.1016/s1016-8478(23)13124-4
72.
GovekEE, NeweySE, Van AelstL. The role of the Rho GTPases in neuronal development. Genes Dev, 2005; 19(1):1–49; doi: 10.1101/gad.1256405
73.
ReadDE, GormanAM. Involvement of Akt in neurite outgrowth. Cell Mol Life Sci, 2009; 66(18):2975–2984; doi: 10.1007/s00018-009-0057-8
74.
Gonzalez-BillaultC, Muñoz-LlancaoP, HenriquezDR, et al.The role of small GTPases in neuronal morphogenesis and polarity. Cytoskeleton (Hoboken), 2012; 69(7):464–485; doi: 10.1002/cm.21034
75.
ZhangZ, OttensAK, LarnerSF, et al.Direct Rho-associated kinase inhibition [correction of inhibiton] induces cofilin dephosphorylation and neurite outgrowth in PC-12 cells. Cell Mol Biol Lett, 2006; 11(1):12–29; doi: 10.2478/s11658-006-0002-x
76.
KalilK, DentEW. Branch management: Mechanisms of axon branching in the developing vertebrate CNS. Nat Rev Neurosci, 2014; 15(1):7–18; doi: 10.1038/nrn3650
77.
IshikawaY, OkadaM, HondaA, et al.Phosphorylation sites of microtubule-associated protein 1B (MAP 1B) are involved in axon growth and regeneration. Mol Brain, 2019; 12(1):93; doi: 10.1186/s13041-019-051
78.
WilkaniecA, CzapskiGA, AdamczykA. Cdk5 at crossroads of protein oligomerization in neurodegenerative diseases: Facts and hypotheses. J Neurochem, 2016; 136(2):222–233; doi: 10.1111/jnc.13365
79.
KanungoJ, ZhengYL, AminND, et al.Targeting CDK5 activity in neuronal degeneration and regeneration. Cell Mol Neurobiol, 2009; 29(8):1073–1080; doi: 10.1007/s10571-009-9410-6
80.
ShahK, LahiriDK. Cdk5 activity in the brain—multiple paths of regulation. J Cell Sci, 2014; 127(Pt 11):2391–2400; doi: 10.1242/jcs.147553
81.
WegmannS, BiernatJ, MandelkowE. A current view on Tau protein phosphorylation in Alzheimer’s disease. Curr Opin Neurobiol, 2021; 69:131–138; doi: 10.1016/j.conb.2021.03.003
82.
MaldonadoH, Ortiz-RiañoE, KrauseB, et al.Microtubule proteins and their post-translational forms in the cerebrospinal fluid of patients with paraparesis associated with HTLV-I infection and in SH-SY5Y cells: An in vitro model of HTLV-I-induced disease. Biol Res, 2008; 41:239–259; doi: 10.4067/S0716-97602008000300001
WangY, YangR, GuJ, et al.Cross talk between PI3K-AKT-GSK-3β and PP2A pathways determines tau hyperphosphorylation. Neurobiol Aging, 2015; 36(1):188–200; doi: 10.1016/j.neurobiolaging.2014.07.035
87.
TaleskiG, SontagE. Protein phosphatase 2A and tau: An orchestrated ‘Pas de Deux’. FEBS Lett, 2018; 592(7):1079–1095; doi: 10.1002/1873-3468.12907
88.
NematullahM, HodaMN, KhanF. Protein phosphatase 2A: A double-faced phosphatase of cellular system and its role in neurodegenerative disorders. Mol Neurobiol, 2018; 55(2):1750–1761; doi: 10.1007/s12035-017-0444-3
89.
SontagJM, SontagE. Protein phosphatase 2A dysfunction in Alzheimer’s disease. Front Mol Neurosci, 2014; 7:16; doi: 10.3389/fnmol.2014.000
90.
SontagJM, SchuhmacherD, TaleskiG, et al.A new paradigm for regulation of protein phosphatase 2A function via Src and Fyn kinase-mediated tyrosine phosphorylation. J Biol Chem, 2022; 298(8):102248; doi: 10.1016/j.jbc.2022.102248
ZhangJN, KochJC. Collapsin response mediator protein-2 plays a major protective role in acute axonal degeneration. Neural Regen Res, 2017; 12(5):692–695; doi: 10.4103/1673-5374.206631
93.
KochJC, TatenhorstL, RoserAE, et al.ROCK inhibition in models of neurodegeneration and its potential for clinical translation. Pharmacol Ther, 2018; 189:1–21; doi: 10.1016/j.pharmthera.2018.03.008
94.
GuanG, CannonRD, CoatesDE, et al.Effect of the Rho-Kinase/ROCK Signaling Pathway on Cytoskeleton Components. Genes (Basel), 2023; 14(2):272; doi: 10.3390/genes14020272
95.
YoshimuraT, ArimuraN, KawanoY, et al.Ras regulates neuronal polarity via the PI3-kinase/Akt/GSK-3beta/CRMP-2 pathway. Biochem Biophys Res Commun, 2006; 340(1):62–68; doi: 10.1016/j.bbrc.2005.11.147
96.
GelfandMV, HongS, GuC. Guidance from above: Common cues direct distinct signaling outcomes in vascular and neural patterning. Trends Cell Biol, 2009; 19(3):99–110; doi: 10.1016/j.tcb.2009.01.001
97.
WangY, OhshimaT. Unraveling the nexus: The role of collapsin response mediator protein 2 phosphorylation in neurodegeneration and neuroregeneration. Neuromolecular Med, 2024; 26(1):45; doi: 10.1007/s12017-024-08814-0
98.
KalinichenkoS, KomkovD, MazurovD. HIV-1 and HTLV-1 transmission modes: Mechanisms and importance for virus spread. Viruses, 2022; 14(1):152; doi: 10.3390/v14010152
99.
ClarkE, NavaB, CaputiM. Tat is a multifunctional viral protein that modulates cellular gene expression and functions. Oncotarget, 2017; 8(16):27569–27581; doi: 10.18632/oncotarget.15174
100.
MucciS, ClasGS, AllioCP, et al.CDK5 deficiency does not impair neuronal differentiation of human induced pluripotent stem cells but affects neurite outgrowth. Mol Neurobiol, 2025; 62(1):918–934; doi: 10.1007/s12035-024-04325-y
101.
ClarkAR, OhlmeyerM. Protein phosphatase 2A as a therapeutic target in inflammation and neurodegeneration. Pharmacol Ther, 2019; 201:181–201; doi: 10.1016/j.pharmthera.2019.05.016
102.
HassanM, YasirM, ShahzadiS, et al.Molecular Role of Protein Phosphatases in Alzheimer’s and other neurodegenerative diseases. Biomedicines, 2024; 12(5):1097; doi: 10.3390/biomedicines12051097
103.
HensleyK, VenkovaK, ChristovA, et al.Collapsin response mediator protein-2: An emerging pathologic feature and therapeutic target for neurodisease indications. Mol Neurobiol, 2011; 43(3):180–191; doi: 10.1007/s12035-011-8166-4
